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ABSTRACT
Background and the purpose of the study: Budesonide is the drug of choice for treatment of active 
inflammatory bowel disease (IBD). The aim of this study was to develop budesonide pellets based 
on a novel colon drug delivery system (CODES). 
Methods: Pellet cores containing lactulose or mannitol were prepared by extrusion/spheronization 
and coated with an acid soluble polymer (Eudragit E100), hydroxypropylmethyl cellulose (HPMC) 
and an enteric coat (Eudragit FS 30D) sequentially. In vitro drug release of coated pellets was 
studied using USP dissolution apparatus type II in buffers of pH 1.2 (2 hrs), pH of 7.4 (4 hrs) 
and pH of 6.8 containing 8% rat cecal contents (RCC) (18 hrs). The efficacy of the optimized 
formulation (containing 50% lactulose coated with Eudragit E (30% w/w) and Eudragit FS 30D 
(12% w/w)) was evaluated against 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in 
rats. 
Results: The results of the kind of bacteria in vitro dissolution tests indicated absence of drug 
release in pHs of 1.2 and 7.4 and controlled release in buffer of pH 6.8 containing RCC. It was 
found that release rate was controlled by the type and amount of polysaccharide and the thickness 
of the acid soluble layer. The prepared formulation showed promising results in alleviating the 
conditions of experimental model of colitis. 
Conclusion: The results of this study suggest that pellets based on CODES technology could be 
useful for colonic delivery of budesonide.
Keywords: Colon targeted delivery, Budesonide, CODES, Extrusion/Spheronization, TNBS-
induced colitis.
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INTRODUCTION
Several diseases such as IBD can be treated more 
effectively by local delivery of anti-inflammatory 
drugs such as 5-aminosalicylic acid and 
corticosteroids to the colon (1). Recently, for the 
delivery of such drugs to intestinal diseased sites, 
much attention has been paid to oral colon drug 
delivery (CDD) systems (2). Newly developed 
corticosteroids with high topical activity and 
low systemic side effects are drugs of choice for 
treatment of IBD (3). Budesonide is a novel synthetic 
corticosteroid with a high ratio of topical to systemic 
anti-inflammatory activity and low systemic effects 
(4). It has gained a primary role in the treatment of 
mild to moderate IBD including ulcerative colitis 
(UC) and Crohn’s disease and now is a drug of the first 
choice in the treatment of active IBD (5). However 
rapid pre-systemic elimination of budesonide in 
hepatocytes and epithelial cells of the small intestine 
wall prevents good bioavailability of this drug in 
colonic mucosa (6).  Thus there remains a significant 
need for an oral CDD system for budesonide in a 
way that maximizes the local concentration in 
inflamed colon mucosa, improves the effectiveness 
of the drug in the treatment of IBD while avoiding 
typical systemic side effects of glucocorticoids. 
CODESTM is a new single unit based technology 
that for release works the principle of pH, time and 
the kind of bacteria (7). This system consists of a 
three layered coated tablet containing a core drug 
and one or more biodegradable polysaccharides. 
The inner coating is an acid-soluble polymer (e.g., 
Eudragit E), the middle layer is a barrier coat and 
the outer layer is an enteric coating. Upon arrival in 
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the colon, the polysaccharide inside the core of the 
tablet dissolves and diffuses out through the inner 
coating of Eudragit E. The colonic local bacteria then 
degrade the polysaccharide into organic acids. This 
lowers the microenvironment pH surrounding the 
formulation, and leads to dissolution of acid-soluble 
coating and subsequent drug release (5). This system 
reduces the variability associated with time, enzyme 
or pH-dependent CDD systems (8). The aim of this 
study was to formulate budesonide pellets based on 
CODESTM technology. To the best of information   
this technique has been used only for single unit 
dosage forms and there is no report on its use on 
the pellet dosage forms. To assess the influence of 
dosage form on the capacity of CODES technology 
for colon targeting, budesonide CODES tablet was 
also prepared according to the formulation of the 
most promising CODES pellets and the dissolution 
profile of two dosage forms were compared. The in 
vivo efficacy of promising formulation was examined 
using the TNBS-induced colitis rat model. 
MATERIAL AND METHODS
Materials 
Budesonide was a kind gift from Astra Zeneca 
(UK). Eudragit E and Eudragit FS 30D (Rohm 
Pharma, Germany), lactulose (Tolid Daru, Iran), 
microcrystalline cellulose as Avicel PH101 (FMC, 
Ireland) lactose monohydrate 200(Meggle, 
Germany); Hydroxypropylmethyl cellulose 6 
cps (Shin-Etsu Chemical Co, Japan), talc and 
triethyl citrate (TEC) (Kirsch Pharma, Germany), 
mannitol (HEBEI HUAXU, China), 2,4,6-
trinitrobenzenesulfonic acid  and prednisolone 
(Sigma Chemical Co., USA) were used in this study. 
All other materials used were of analytical reagent 
grade and purchased from Merck Co. (Darmstadt, 
Germany).
Preparation of CODES budesonide pellets 
Preparation of core pellets 
Budesonide core pellets were prepared by the 
extrusion-spheronization method in a laboratory 
scale extruder (Model 20, Caleva, UK), fitted with 
a spheronizer (model 250, Caleva,
 
UK). The details 
of the composition of the prepared formulations are 
given in table 1. Pellets of the size of 840-1000 µm 
were used in subsequent coating. 
Preparation of coated pellets
Three layers of polymeric coatings at different 
operating conditions (Table 2) were applied to drug 
loaded pellets in the following order using a top 
spray fluidized bed coater (VECTOR Corporation, 
Marion, Iowa): Eudragit E layer(12% Eudragit E 
100, 2.4% TEC, and 1.2% talc  in mixture of ethyl 
alcohol/water, 60:40) at 20%, 25%, 30% and 35% 
(w/w), HPMC layer (5.71% HPMC, 1.71% TEC, 
and 2.65% talc  in water) at 6% (w/w) and Eudragit 
FS 30D layer (15% Eudragit FS 30D and  7.5% talc 
in water) at 12% (w/w) weight gain. 
Preparation of CODES budesonide tablets
Bi-convex tablet cores (200 mg) containing 3 mg 
budesonide were prepared using a single punch tablet 
machine (ERWEKA, Germany) which contained 
budesonide (1.5%), lactose (18.5%), lactulose 
(50%), microcrystalline cellulose (30%) and 
magnesium stearate (0.5%) added extragranularly. 
The three layers of polymeric coating were applied 
to core tablets with the same formulations and in the 
same order explained earlier using a conventional 
pan-coating process in a pan coater (ERWEKA, 
Germany). The coating weight gain for Eudragit 
E100, HPMC and Eudragit FS 30D were 8%, 2%, 
and 5% w/w, respectively.
In vitro release experiments 
Budesonide release study
Dissolution tests were performed on pellets containing 
3 mg of budesonide using paddle method (USP 
apparatus II). The rotating speed was 50 rpm at 
37±0.5 °C. Dissolution test of uncoated pellets was 
performed in phosphate buffer saline (PBS) of pH 6.8 
(250 ml) for 3 hrs. The release of Eudragit E coated 
pellets was evaluated in PBS of pH of 6.8 (250 ml) for 
24 hrs. The influence of the
 
type and concentration of 
polysaccharide (mannitol or lactulose) was evaluated 
in PBS of pH of 7.4 (250 ml) for 4 hrs and in PBS of pH 
of 6.8 (100 ml) in the presence or absence of 8% RCC 
for 18 hrs under continuous supply of CO2, to simulate 
the colon environment. Preparation of RCC containing 
media was carried out according to a reported method 
(9). To determine the dissolution profile of the most 
promising CODES pellet formulation and budesonide 
CODES tablet in simulated gastrointestinal (GI) 
fluids, a dissolution test was performed using three 
consecutive media as mentioned above and 0.1 N 
HCl (250 ml) for the first 2 hrs.  In all drug release 
studies 0.5 percent (w/v) of sodium lauryl sulphate 
was used in each dissolution medium to maintain sink 
conditions. Dissolution samples of a certain volume 
were withdrawn at 2, 4, 6, 8, 10, 12, 14, 16, 18 and 24 
hrs and replaced with fresh solution. The amount of 
released budesonide was determined using an HPLC 
method described below.
Lactulose / Mannitol release study 
Lactulose and mannitol release studies were 
performed in 250 ml PBS of pH 6.8 for 12 hrs under 
the same conditions described above. Lactulose 
concentration was determined by a reported method   
(10) and mannitol concentration was determined by 
the USP method (11). 
HPLC analysis
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assay and dissolution studies was performed by 
HPLC method equipped with UV detector using 
dexamethasone as an internal standard (12). The 
analysis was carried out by using a Shimpack C8 
column (150 mm × 4.6 mm, 5 mm particle size) at a 
wavelength of 244 nm. The mobile phase consisted 
of acetonitrile, monobasic potassium phosphate 
(0.025 M) (55:45, pH of 3.2). The flow rate was 1.0 
ml/min and injection volume of 20 μl. Quantitation 
was achieved by measurement of the peak area ratios 
of the drug to the internal standard. The retention 
time of the budesonide chromatographic peak was 
found at 5 min.
Scanning electron microscope (SEM) studies
The morphology of optimized formulations of 
uncoated and coated pellets was characterized using 
SEM. The Samples were gold coated using a sputter 
coater and then analyzed using SEM (Philips, XL30, 
Philips, Eindhoven, Netherlands).  
In vivo study
Induction of colitis and treatment
Colitis was induced according to the method of 
Morris  et  al.  (13)  by  some  modification.  Male 
Wistar rats (180-220 g) were randomly assigned 
to groups of six. Following a 24 hrs fasting, rats 
were anesthetized and TNBS (20 mg) dissolved 
in 0.5 ml of ethanol (40% v/v) was instilled 
into the colon up to 8 cm intra-rectally using a 
polyethylene tube (2 mm in diameter). After 24 
hrs, budesonide CODES pellets (300 µg/kg/day, 
oral) were administered via a NG tube (No. 8) 
fixed on a feeding tube No. 18 (group C) for 7 
days. Different control and treatment groups were 
used: A: normal control group received only 0.5 
ml normal saline, B: colitis control group received 
TNBS and treated with normal saline, D: FS 30D 
coated pellets (without Eudragit E layer ) (300 
µg/kg/day), E: free polysaccharide coated pellets 
(300 µg/kg/day), F: budesonide solution (300 µg/
kg/day), G: uncoated pellets (300 µg/kg/day), H: 
placebo pellets, I: mesalazine enema (400 mg/kg/
day), J: budesonide enema (20 mcg/kg/day) and 
K: prednisolone (5mg/kg/day,orally). All animal 
experiments were performed in compliance with 
the guidelines of ethics committee of Isfahan 
University of Medical Science.
Batch Code
Budesonide
(%)
Avicel PH101
(%)
Lactose
(%)
Mannitol
(%)
Lactulose
(%)
Granulating liquid
(Water) (g)
yield
(%)
Mean pellet 
size (µm)
Drug Released (%) after 
2h +SD (pH 6.8)
F1 1.5 98.5 - - - 58.2 92.1 998.98 10+0.89
F2 1.5 30 68.5 - - 46.5 98.1 922.20 32+2.70
F3 1.5 30 58.5 - 10 42 80.2 920.14 38.8+2.13
F4 1.5 30 48.5 - 20 37.3 83.9 911.38 58.2+3.35
F5 1.5 30 38.5 - 30 34.5 86.8 897.56 69.3+2.50
F6 1.5 30 33.5 - 35 32 87 924.9 82.4+1.62
F7 1.5 30 28.5 - 40 30.5 88.4 903.5 85.9+3.91
F8 1.5 30 18.5 - 50 28.4 89.5 926.9 91.5+4.13
F10 1.5 30 48.5 20 - 42 80.4 900.5 40+0.8
F11 1.5 30 28.5 40 - 40.5 78.8 896.2 61.5+3.8
F12 1.5 30 8.5 60 - 37 70.5 879.8 83+5.1
F13 1.5 18.5 - 80 - 35.4 59.8 656.4 -
Table 1. Different budesonide pellet core formulations prepared by extrusion spheronization method.
Operating condition
Acid resistance coating with 
Eudragit E
Barrier coating with 
HPMC
Enteric coating with 
Eudragit FS 30D
Before coating preheating to (ºC) - - 33 º
Coating nozzle diameter (mm) 1 1 1.2
Spraying rate (g/min) 2 0.4 2
 Inlet air temperature (ºC) 30-32 70-72 35-42
Outlet air temperature (ºC)   25-27 56-58 25-28
Curing in fluid bed  30 min at 35 ºC - -
on trays - 48 hrs at room temperature 24 hrs at 40 ºC
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Assessment of colitis 
Rats were euthanized 24 hrs after the treatment for 
7 days. Using the distal portion of the colon (8 cm), 
weight ratios of colon wet weight versus rat body 
(mg/g) and ulcer surface area were measured (14) and 
macroscopic damage score was calculated according 
to the criteria reported previously (15).  The modified 
scoring system is: 0, normal appearance; 1, erythema 
and  inflammation  without  ulcer;  2,  Inflammation 
and ulcer; 3, ulcer with necrosis. After macroscopic 
evaluation, full thickness biopsy specimens were 
fixed in 10% buffered formalin solution, embedded 
in  paraffin,  stained  with  haematoxylin  and  eosin 
(H & E) and subjected to the histopathological 
studies. Microscopic evaluation was performed 
by a pathologist unaware of the study design. The 
histological scoring was carried out as previously 
described (16) with a slight modification according 
to the criteria shown in table 3. 
Statistical analyses
The data of drug released at the end of each 
dissolution test were analyzed using one-way 
analysis of variance (ANOVA). The in vivo data 
were expressed as mean±SEM. Differences between 
mean values of colon weight/body weight  ratio and 
ulcer surface area were analyzed using ANOVA 
followed by a Dunnett’s post hoc. Comparison 
between macroscopic and microscopic damage 
scores were performed using Mann-Whitney U-test 
and p<0.05 was considered significant in all cases.
RESULTS AND DISCUSSION
In vitro results
Budesonide core pellets were prepared successfully 
by extrusion-spheronization method using lactulose 
or mannitol as main excipients.  These saccharides 
pass into the colon unchanged, hydrolyzed rapidly and 
degraded by colonic enterobacteria to organic acids 
(17, 18).
It is the first time that lactulose is used as an excipient 
for pellet preparation. The surfaces of the pellets of 
two types of formulations were smooth and spherical. 
However, lactulose containing pellets compared to 
those containing mannitol were smoother (Figs.1A, 
B). Figures 2a and 2b show budesonide release 
from lactulose and mannitol containing pellet cores 
respectively. While lactulose improved budesonide 
release rate even at concentration of 35%, mannitol was 
ineffective in concentrations below 60% w/w. Based 
on these results the core formulations containing 
35, 40 and 50% lactulose and 60% mannitol were 
selected as optimum for the coating processes.
The effect of Eudragit E layer thickness on 
budesonide  release  is  presented  in  figure  3a. 
Pellets which were coated to weight increase of 30% 
(w/w) showed 29.3% of drug release at the end of 
dissolution time after a lag time of 8 hrs which was 
enough to retard the drug release under the conditions 
of  simulated  intestinal  fluid  (19).  However,  the 
overall budesonide release was very low to ensure 
drug targeting. 
Figures 3b and 3c show the effect of Eudragit 
E coating level on the polysaccharide release. 
Expectedly, the higher the coating levels, the slower 
the polysaccharide release. However, retardation of 
lactulose release was achieved with thicker Eudragit 
E layer in comparison to mannitol perhaps due to 
higher water solubility of lactulose. A comparison 
of figures 3a, 3b and 3c, shows that mannitol and 
lactulose were released at a much higher rate 
than  budesonide  which  could  guarantee  sufficient 
acidification  of  microenvironments  around  pellets 
(10).  
The  influence  of  the  type  of  polysaccharide  on 
drug release is shown in figure 4a. The release of 
budesonide from lactulose containing pellets in the 
presence of RCC were faster than those without RCC 
(82.5% versus 29.3%, p<0.05) which show that the 
release under the physiological condition of colon is 
under influence of microbial degredation of lactulose 
(20). In contrast, addition of RCC to dissolution 
medium, had no effect on the release of budesonide 
from mannitol containing pellets (39.2% versus 
33.8%) (p>0.05). These results may be explained 
either by very low concentration of enzymes 
responsible for hydrolysis of mannitol or the low rate 
of hydrolysis of mannitol. Based on these findings, it 
seems that only easily fermentable polysaccharides 
such as lactulose with high fermentation rate (21) 
and water solubility (≈75 g/100 ml) were suitable for 
this formulation design. Figure 4b shows the effect 
of lactulose concentration on the drug release. As the 
lactulose concentration increased in the pellet cores, 
drug release increased (43.4%, 54.7% and 82.5%, 
respectively) which were higher than those without 
RCC (29%, p<0.05). Another parameter which was 
affected by the concentration of lactulose was the lag 
Scoring parameter Score definition
Inflammation severity
0: None
1: Mild
2: Moderate
3: Severe
Inflammation extent
0: None
1: Mucosa
2: Mucosa and submucosa
3: Transmural
Crypt damage
0: None
1: Basal 1/3 damaged
2: Basal 2/3 damaged
3: Crypts lost, surface epithelium present
4: Crypts lost, surface epithelium lost
Table  3. Scoring system for histopathological assessment of 
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time of drug release which decreased as the amount 
of lactulose increased. The lag time of 50% lactulose 
containing pellets in the presence of RCC was 6 hrs 
and in its absence was 8 hrs. 
The drug release characteristics of budesonide 
CODES tablet and optimized pellet formulation 
containing 50% lactulose coated with 30% Eudragit 
E and 12% Eudragit FS 30D are shown in figure 
4c. In the absence of RCC, the drug release from 
tablet formulation was slower than that of pellets 
(p<0.05) with longer lag time which might be due 
to lower surface area of tablets.  However, in the 
presence of RCC, the drug release from tablets was 
higher than pellets (p<0.05). The tablets showed no 
release up to the end of 8th hour, released 80% of 
the drug in the next 6 hrs and released was almost 
complete after 24 hrs. In contrast, pellets after a 
lag time of 6 hrs released their contents gradually 
during 18 hrs.
In vivo study
Figure 5A shows a normal colon with no 
macroscopic damage. In contrast the colon in colitis 
control group was severely damaged, showing the 
mucosal congestion, haemorrhage, deep ulcers 
and budesonide (Fig.5B). Oral administration of 
budesonide-CODES pellets significantly healed the 
damaged colon (Fig. 5C) and was more effective 
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Figure 1 
Figure 1. SEM micrographs of budesonide pellets containing A) lactulose, B) mannitol, C) Eudragit E coating and D) Eudragit FS 30D 
coating with ×50 and ×60  magnification.Development of novel budesonide pellets  112
than other treatment groups (p<0.05) except the 
groups treated with oral prednisolone (Fig. 5K) and 
budesonide enema (Fig.5J). After oral administration 
of budesonide CODES pellets, colon/body weight 
ratio  decreased  significantly  (p<0.05)  compared 
to colitis group. Further, a better therapeutic effect 
was observed after administration of budesonide 
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Figure 2 
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Figure 2. Effect of a) lactulose and b) mannitol amount on budesonide release from core pellets in PBS (pH 6.8 containing 0.5% SLS).
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CODES pellets compared to budesonide solution 
(22), budesonide uncoated pellets, FS 30D coated 
pellets and lactulose free coated pellets (p<0.05). 
This significant decrease in colon/body weight ratio 
was comparable to the group treated with mesalazine 
enema and budesonide enema (p>0.05). The percent 
of ulcerative area was also decreased in the group 
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Figure 3 continued 
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Figure 3 continued 
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Figure 3. Effect of Eudragit E layer thickness on a) budesonide b) lactulose c) mannitol release from coated pellets.
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Figure 4. Effect of a) polysaccharide type b) polysaccharide amount  c) Dosage form on budesonide release
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Figure 5. Representative macroscopic appearance of rat colonic mucosa. A= Normal control, B= colitis control, C= Budesonide CODES 
pellets (300 µg/kg/day) improved TNBS–induced colitis and decreased the ulcer surface, D= FS 30D coated pellets, (300 µg/kg/day), 
E= Lactulose free coated pellets (300 µg/kg/day ), F= Budesonide solution (300 µg/kg/day), G=Budesonide uncoated pellet (300 µg/kg/
day), H= Placebo pellets, I= Mesalazine enema (400 mg / kg/day, rectally), J=Budesonide enema (20 mcg/kg/day, rectally) 
and K= Prednisolone (5 mg / kg / day, oral) groups.
Figure 6. Representative histological appearance of rat colonic mucosa. A= Normal control, B= Colitis control, C= Budesonide CODES 
pellets (300 µg/kg/day): The degree of inflammatory cell infiltrate was markedly reduced and there was a near absence of hemorrhage 
in the mucosa. However crypt structure had not returned to control levels, D=FS 30D coated pellets (300 μg/kg/day ), E= Lactulose free 
coated pellets (300 µg/kg/day ), F= Budesonide solution (300 µg/kg/day), G= Budesonide uncoated pellets (300 µg/kg/day), H= Placebo 
pellets, I= Mesalazine enema (400 mg/kg/day, rectally), J=Budesonide enema (20 mcg/kg/day, rectally) and K= Prednisolone (5 mg / kg 
/ day, oral). Hematoxylin and eosin stain and original magnification 10×.Development of novel budesonide pellets  116
treated with budesonide CODES pellets and groups 
of prednisolone, mesalazine enema and budesonide 
enema (p<0.05).  Table 4 summarizes the data of 
macroscopic evaluation of colon damage of control 
and treatment groups.
Figure 6A shows the histology of normal colon. As 
it is shown in figure 6B other than inflammatory 
cellular infiltration, the colitis induced colon showed 
extensive necrotic destruction of epithelium, 
hemorrhage, edema, crypt damage and ulceration 
at mucosal and sub-mucosal layers. Examination 
of the histopathology slides (Fig. 6 A-K) revealed 
a dramatic decrease in the mucosal injury after 
Groups A B C D E F G H I J K
Body weight difference (g) 28.3±1.6 -34±5.0 13.8±3.5* -2.3±2 -13.2±2.8 3.5±2.7 6±2.8 -20±3.2 -5±5.1 17.8±1.7 -9±6.9
Colon /Body ratio (mg/g) 2.5±0.7 12.9±0.7 5.9±1* 7.3±0.7 10.9±0.8 9.1±0.2 8.3±0.2 11.7±0.9 5.5±0.3 4.7+0.4 3.6±0.6
Ulcerative area(%)  0.0+0.0 69.7±5.3 16.2±5* 40.8±9 54.5±6.4 50.2±4.1 51.8±3.7 71.8±3.9    40±7.8     24±6.5 13.3±4.9
Macroscopic score 0.0±0.0 3.0±0.0 2.2±0.2* 2.3±0.4 2.5±0.3 2.7±0.2 2.5±0.3 2.8±0.4 2.7±0.2 2.1±0.4 2.0±0.08
A= Normal control, B= Colitis control, C= Budesonide CODES pellets (300 µg/kg/day), D=FS 30D coated pellets (300 µg/kg/day), E= Lactulose free coate 
pellets (300 µg/kg/day), F= Budesonide solution (300 µg/kg/day ), G= Budesonide uncoated pellets (300 µg/kg/day), H= Placebo pellets I= Mesalazine 
enema (400 mg / kg/day, rectally) J= Budesonide enema (20 mcg/kg/day, rectally) and K= Prednisolon (5 mg / kg / day, oral). The results were expressed 
as arithmetic mean ± SEM, (n=6)
*p<0.05 denote significant difference vs negative control group. 
Table 4. Data of clinical score and macroscopic evaluation of colitis in control and treatment groups after 7 days treatment.
Groups IS IE CD TMS
A 0±0 0+0 0±0 0±0
B 2.83±0.15 2.83±0.15 3.28±0.47 8.14+1.32
C 2.33±0.38 1.83±0.36 1.28±0.64 5.28±1.08*
D 2.41±0.74 2.36±0.39 2.98±0.86 6.94±0.66
E 2.75±0.45 2.59±0.47 3.34±0.52 7.45± 0.74
F 2.33±0.30 2.16±0.36 3.70±0.28 7.57±0.89
G 2.50±0.20 2.16±0.27 2.83±0.76 7.0±0.97
H 2.66±0.20 2.66±0.36 3.0±0.8 7.57±0.71
I 2.83±0.15 2.66±0.19 2.28±0.99 6.14±1.15
J 3.0±0.90 2.50±0.20 2.57±1.1 6.85±0.46
K 2.16±0.36 1.66±0.19 1.85±1.30 4.71±1.14
A= Normal control, B=Colitis control, C= Budesonide CODES pellets (300 µg/kg/day), D=FS 30D coated pellets (300 µg/kg/day), 
E= Lactulose free coated pellets (300 µg/kg/day), F= Budesonide solution (300 µg/kg/day ) G=Budesonide uncoated pellets (300 
µg/kg/day), H= Placebo pellets, I= Mesalazine enema (400 mg / kg/day, rectally) J= Budesonide enema (20 mcg/kg/day, rectally) 
and K= Prednisolone (5 mg / kg / day, oral). IS= Inflammation Severity, IE= Inflammation Extent, CD= Crypt Damage, TMS= Total 
Microscopic Score. The results were expressed as arithmetic mean ± SEM, (n=6)
*p<0.05 denote significant difference vs colitis control groups
Table 5. Data of histopathologic evaluation of colitis in control and treatment groups after 7 days treatment.
treatment with CODES pellets (Fig. 6C). The degree 
of inflammatory cell infiltrate was markedly reduced 
and almost no hemorrhage was observed in the 
mucosa. Table 5 shows the means of histological 
parameters in colon tissue for each group. All 
groups treated with prednisolone, mesalazine 
enema, budesonide enema and budesonide CODES 
pellets, showed histological improvement compared 
to colitis control group and could attenuate the total 
histological score of colitis (p<0.05). 
From the results of this study it seems that CODES 
budesonide pellets could be used to enhance the 
effectiveness of budesonide in treatment of IBD.
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